Clinical trial · Observational
Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment
Multicenter Real-world Study on the Efficacy and Safety of DS8201 in the Treatment of Metastatic Breast Cancer
NCT06914661CI-TRIAL-00091828EASOFDIMBCTenrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study analyzes the use of DS8201 in the treatment of metastatic breast cancer in the real world by analysis, exploring whether there are differences in effectiveness and safety between real-world conditions and clinical trials.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Metastatic | — | UNRESOLVED | — |
| Efficacy and Safety | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- PFS
- timeFrame
- baseline and 1 year
- description
- Time to disease progression or death from the first receipt of treatment in each line of therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion criteria: (1) age ≥18 years old; (2) breast cancer confirmed by pathological diagnosis; (3) the presence of one or more distant metastatic lesions confirmed by pathology or imaging; (4) patients had received DS8201 treatment; (5) Complete medical records, complete blood routine and liver and kidney function test results during treatment. Exclusion criteria: no history of traceable or missing clinical data.
References
Publications (0)
Data not yet available
No reference posted for this study.